
    
      In this protocol, we plan to identify specific markers from biochemical, proteomic,
      epigenetic and molecular genetic analyses that predict clinical outcome, responsiveness to
      therapy and might serve as promising therapeutic targets in patients with soft tissue
      sarcoma.
    
  